Yayın:
Nivolumab for relapsed or refractory <scp>H</scp>odgkin lymphoma: Experience in <scp>T</scp>urkey

Sadeleştirilmiş öğe sayfası
dc.contributor.authorGülbaş, Zafer
dc.contributor.authorHüseyin Saffet Beköz
dc.contributor.authorNuri Karadurmuş
dc.contributor.authorSemra Paydaş
dc.contributor.authorZafer Gülbaş
dc.contributor.authorAlev Türker
dc.contributor.authorTayfur Toptaş
dc.contributor.authorTülin Tuğlular
dc.contributor.authorEmre Tekgündüz
dc.contributor.authorAli Kaya
dc.contributor.authorN. Taştemir
dc.contributor.authorMutlu Arat
dc.contributor.authorFunda Pepedil Tanrıkulu
dc.contributor.authorVildan Özkocaman
dc.contributor.authorHüseyin Abalı
dc.contributor.authorMehmet Turgut
dc.contributor.authorLeylagül Kaynar
dc.contributor.authorÌhsan Karadoǧan
dc.contributor.authorMurat Özbalak
dc.contributor.authorM. Dogu
dc.contributor.authorSibel Hacıoğlu
dc.contributor.authorRahşan Yıldırım
dc.contributor.authorİbrahim Barışta
dc.contributor.authorMeltem Kurt Yüksel
dc.contributor.authorMehmet Sönmez
dc.contributor.orcid0000-0002-4257-549X
dc.contributor.orcid0000-0003-1237-8281
dc.contributor.orcid0000-0003-3291-8062
dc.contributor.orcid0000-0003-4642-3693
dc.contributor.orcid0000-0002-4709-0627
dc.contributor.orcid0000-0001-5265-8128
dc.contributor.orcid0000-0002-2690-8581
dc.contributor.orcid0000-0001-9967-2357
dc.contributor.orcid0000-0002-6388-9658
dc.contributor.orcid0000-0003-2039-8557
dc.contributor.orcid0000-0003-1878-1872
dc.contributor.orcid0000-0003-0014-7398
dc.contributor.orcid0000-0002-5272-8672
dc.contributor.orcid0000-0002-1036-0232
dc.contributor.orcid0000-0002-2035-9462
dc.contributor.orcid0000-0002-3040-4052
dc.contributor.orcid0000-0003-0757-9206
dc.contributor.orcid0000-0002-5717-3936
dc.contributor.orcid0000-0002-5733-439X
dc.contributor.orcid0000-0003-0369-299X
dc.contributor.orcid0000-0002-2176-4371
dc.date.accessioned2025-11-13T22:52:28Z
dc.date.issued2017-06-01
dc.identifier.doihttps://doi.org/10.1002/hon.2439_63
dc.identifier.endpage323
dc.identifier.issn0278-0232
dc.identifier.issueS2
dc.identifier.openalexW2622350361
dc.identifier.startpage321
dc.identifier.urihttps://hdl.handle.net/11421/15591
dc.identifier.urihttps://doi.org/10.1002/hon.2439_63
dc.identifier.volume35
dc.language.isoen
dc.relation.ispartofHematological Oncology
dc.rightsopenAccess
dc.subjectMedicine
dc.subjectNivolumab
dc.subjectBrentuximab vedotin
dc.subjectRefractory (planetary science)
dc.subjectInternal medicine
dc.subjectRadiological weapon
dc.subjectSurgery
dc.subjectOncology
dc.subjectLymphoma
dc.subjectHodgkin lymphoma
dc.subjectImmunotherapy
dc.subjectCancer
dc.subject.sdg2
dc.titleNivolumab for relapsed or refractory <scp>H</scp>odgkin lymphoma: Experience in <scp>T</scp>urkey
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5058571002

Dosyalar

Koleksiyonlar

Publications